Veracyte CFO Rebecca Chambers sells $157,394 in VCYT shares

Rebecca Chambers, Chief Financial Officer of VERACYTE, INC. (NASDAQ:VCYT), disposed of company common stock totaling $157,394 on September 4, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which was adopted by Ms. Chambers on August 21, 2025. The sales come as VCYT shares trade at $42.53, with the stock currently appearing on the most overvalued list according to InvestingPro analysis.

Ms. Chambers sold a total of 3,652 shares of VERACYTE common stock. The transactions occurred at weighted average prices of $42.8059 and $43.714 per share, with individual sale prices ranging from $42.49 to $44.16.

Separately, on September 2, 2026, Ms. Chambers also disposed of 3,603 shares of VERACYTE common stock at $44.88 per share, totaling $161,702. This transaction satisfied tax withholding obligations related to the vesting of restricted stock units and does not represent a sale by the executive. Following these reported transactions, Ms. Chambers beneficially owns 166,025 shares of VERACYTE common stock directly. The company maintains a "GREAT" financial health score of 3.68 out of 5, according to InvestingPro metrics. For deeper insights into VCYT’s valuation and financial strength, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Veracyte, Inc reported impressive second-quarter 2026 earnings, surpassing Wall Street’s expectations with adjusted earnings of $0.54 per share on revenue of $150.3 million. This performance exceeded forecasts of $0.43 per share and $144.6 million in revenue. The company also raised its full-year revenue outlook, reflecting its strong financial position. Following these results, several analyst firms adjusted their price targets for Veracyte. Freedom Capital increased its price target to $66, citing the strong earnings and revenue figures. Needham also raised its target to $69, emphasizing the company’s revenue and earnings per share beat. Meanwhile, Canaccord lowered its price target to $50 due to a more cautious revenue outlook in the long term, despite acknowledging the strong second-quarter performance. These developments highlight varying analyst perspectives on Veracyte’s future growth potential.